Cancer imaging and therapy with bispecific antibody pretargeting

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma

Jacques Barbet, L. Campion, Françoise Kraeber‐Bodéré et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 407 citations

Medicine, Oncology, Surgery +17

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Klaus Brischwein, Bernd Schlereth, Benjamin Guller et al. · Molecular Immunology · 2005 · 260 citations

Pharmacy, Medicinal Chemistry, Oncology +14

Antibodies against metal chelates

Dayton T. Reardan, Claude F. Meares, David A. Goodwin et al. · Nature · 1985 · 260 citations

Natural Sciences, Chemistry, Inorganic Chemistry +2

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

Donald B. Axworthy, J. M. Reno, Mark D. Hylarides et al. · Proceedings of the National Academy of Sciences · 2000 · 230 citations

Medicine, Oncology, Pharmacology +17